{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:25:29Z","timestamp":1786987529457,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105279","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:12:27Z","timestamp":1773504747000},"page":"105279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Immunotherapy failure in glioblastoma: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6349-5301","authenticated-orcid":false,"given":"Tomasz","family":"Tykocki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"28","key":"10.1016\/j.critrevonc.2026.105279_bib1","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105279_bib2","article-title":"Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma","volume":"30","author":"Barish","year":"2022","journal-title":"Neoplasia N. Y N."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105279_bib3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105279_bib4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/WCO.0b013e328332363e","article-title":"Pseudoprogression and pseudoresponse in the treatment of gliomas","volume":"22","author":"Brandsma","year":"2009","journal-title":"Curr. Opin. Neurol."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105279_bib5","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"5-6","key":"10.1016\/j.critrevonc.2026.105279_bib6","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.wneu.2011.08.020","article-title":"Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial","volume":"77","author":"Cho","year":"2012","journal-title":"World Neurosurg."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105279_bib7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105279_bib8","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","article-title":"Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial","volume":"6","author":"Cloughesy","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105279_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s40364-025-00863-2","article-title":"Glioma tumor microenvironment and immunotherapy: past, present, and future","volume":"13","author":"Cvitkovi\u0107","year":"2025","journal-title":"Biomark. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105279_bib10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105279_bib11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1101\/gad.187922.112","article-title":"Emerging insights into the molecular and cellular basis of glioblastoma","volume":"26","author":"Dunn","year":"2012","journal-title":"Genes Dev."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105279_bib12","first-page":"1017","article-title":"Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival","volume":"25","author":"Ellingson","year":"2023","journal-title":"NeuroOncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105279_bib13","first-page":"307","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105279_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10143-025-04043-6","article-title":"Efficacy and safety of immune checkpoint inhibitors and mTOR inhibitors as targeted therapy for glioblastoma: a systematic review and meta-analysis of randomized clinical trials","volume":"49","author":"G\u00f3mez","year":"2026","journal-title":"Neurosurg. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105279_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat. Neurosci."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105279_bib16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105279_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11060-020-03598-2","article-title":"Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor","volume":"151","author":"Hotchkiss","year":"2021","journal-title":"J.Neurooncol"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105279_bib18","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of immunotherapy resistance: lessons from glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105279_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00108","article-title":"Tumor response end points as surrogates for overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis","author":"Kok","year":"2021","journal-title":"JCO Precis Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105279_bib20","first-page":"1935","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"NeuroOncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105279_bib21","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105279_bib22","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","article-title":"Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma","volume":"27","author":"Nayak","year":"2021","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105279_bib23","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105279_bib24","first-page":"123","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","volume":"25","author":"Omuro","year":"2022","journal-title":"NeuroOncol."},{"issue":"399","key":"10.1016\/j.critrevonc.2026.105279_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105279_bib26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105279_bib27","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.3390\/cancers15133274","article-title":"Evaluation of RANO Criteria for the Assessment of Tumor Progression for Lower-Grade Gliomas","volume":"15","author":"Raman","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105279_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105279_bib29","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-18-1140","article-title":"Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial","volume":"26","author":"Reardon","year":"2020","journal-title":"Clin. Cancer Res J. Am. Assoc. Cancer Res"},{"issue":"31","key":"10.1016\/j.critrevonc.2026.105279_bib30","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","article-title":"Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma","volume":"28","author":"Sampson","year":"2010","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105279_bib31","article-title":"Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma","volume":"3","author":"Schritz","year":"2021","journal-title":"NeuroOncol. Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105279_bib32","article-title":"NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma","volume":"5","author":"Sim","year":"2023","journal-title":"NeuroOncol. Adv."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105279_bib33","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105279_bib34","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105279_bib35","article-title":"The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review","volume":"4","author":"Swildens","year":"2022","journal-title":"NeuroOncol.Adv."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105279_bib36","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105279_bib37","article-title":"Active immunotherapy for glioblastoma treatment: a systematic review and meta-analysis","volume":"29","author":"Wahyuhadi","year":"2022","journal-title":"Cancer Control J. Moffitt Cancer Cent."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105279_bib38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3390\/cancers17050855","article-title":"Trends in efficacy endpoints in phase II glioblastoma trials: a regulatory science analysis (FY2020\u2013FY2022)","volume":"17","author":"Watanabe","year":"2025","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105279_bib39","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105279_bib40","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1158\/1078-0432.CCR-19-0261","article-title":"A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma","volume":"25","author":"Wen","year":"2019","journal-title":"Clin. Cancer Res J. Am. Assoc. Cancer Res"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105279_bib41","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105279_bib42","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.canlet.2017.06.024","article-title":"Targeting EGFRvIII for glioblastoma multiforme","volume":"403","author":"Yang","year":"2017","journal-title":"Cancer Lett."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:46:19Z","timestamp":1778481979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":42,"alternative-id":["S1040842826001666"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105279","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy failure in glioblastoma: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105279"}}